Carbamate/urea derivatives
US-9273026-B2 · Mar 1, 2016 · US
Carbamate/urea derivatives
US9624192B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9624192-B2 |
| Application number | US-201615049739-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 22, 2016 |
| Priority date | Jul 20, 2012 |
| Publication date | Apr 18, 2017 |
| Grant date | Apr 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of ameliorating obesity comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 2. A method of ameliorating epilepsy comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihydropyridazin-3-yl) piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 3. A method of ameliorating narcolepsy comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin--yl 4-cyclobutylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 4. A method of ameliorating narcolepsy in a subject in need of treatment thereof comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihydropyridazin -3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate, or a salt thereof, in combination with another active agent selected from the group consisting of: a noradrenaline-dopamine reuptake inhibitor, a tri- or tetracyclic antidepressant, a serotonin-noradrenaline reuptake inhibitor, a selective serotonin reuptake inhibitor, a noradrenaline reuptake inhibitor, a MAO-B inhibitor, a gamma-hydroxy-butyrate and a psychostimulant. 5. A method according to claim 4 wherein the other active agent is selected from the group consisting of: modafinil, armodafinil, clomipramine, venlafaxine, duloxetine, paroxetine, reboxetine, atomoxetine, selegiline and methylphenidate. 6. A method of ameliorating obesity comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 7. A method of ameliorating epilepsy comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-l-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 8. A method of ameliorating narcolepsy comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-l-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 9. A method of ameliorating narcolepsy in a subject in need of treatment thereof comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-l-carboxylate, or a salt thereof, in combination with another active agent selected from the group consisting of: a noradrenaline-dopamine reuptake inhibitor, a tri- or tetracyclic antidepressant, a serotonin-noradrenaline reuptake inhibitor, a selective serotonin reuptake inhibitor, a noradrenaline reuptake inhibitor, a MAO-B inhibitor, a gamma-hydroxy-butyrate and a psychostimulant. 10. A method according to claim 9 wherein the other active agent is selected from the group consisting of: modafinil, armodafinil, clomipramine, venlafaxine, duloxetine, paroxetine, reboxetine, atomoxetine, selegiline and methylphenidate. 11. A method of ameliorating obesity comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihy dropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 12. A method of ameliorating epilepsy comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 13. A method of ameliorating narcolepsy comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-l-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 14. A method of ameliorating narcolepsy in a subject in need of treatment thereof comprising administration of an effective amount of the compound 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-isopropylpiperazine-l-carboxylate, or a salt thereof, in combination with another active agent selected from the group consisting of: a noradrenaline-dopamine reuptake inhibitor, a tri- or tetracyclic antidepressant, a serotonin-noradrenaline reuptake inhibitor, a selective serotonin reuptake inhibitor, a noradrenaline reuptake inhibitor, a MAO-B inhibitor, a gamma-hydroxy-butyrate and a psychostimulant. 15. A method according to claim 14 wherein the other active agent is selected from the group consisting of: modafinil, armodafinil, clomipramine, venlafaxine, duloxetine, paroxetine, reboxetine, atomoxetine, selegiline and methylphenidate. 16. A method of ameliorating obesity comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 17. A method of ameliorating epilepsy comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 18. A method of ameliorating narcolepsy comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutylpiperazine-1-carboxylate, or a salt thereof, to a subject in need of treatment thereof. 19. A method of ameliorating narcolepsy in a subject in need of treatment thereof comprising administration of an effective amount of the compound 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yOpiperidin-4-yl 4-cyclobutylpiperazine-l-carboxylate, or a salt thereof, in combination with another active agent selected from the group consisting of: a noradrenaline-dopamine reuptake inhibitor, a tri- or tetracyclic antidepressant, a serotonin-noradrenaline reuptake inhibitor, a selective serotonin reuptake inhibitor, a noradrenaline reuptake inhibitor, a MAO-B inhibitor, a gamma-hydroxy-butyrate and a psychostimulant. 20. A method according to claim 19 wherein the other active agent is selected from the group consisting of: modafinil, armodafinil, clomipramine, venlafaxine, duloxetine, paroxetine, reboxetine, atomoxetine, selegiline and methylphenidate.
Assignees
Inventors
Classifications
Immunostimulants · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the nervous system · CPC title
- C07D401/14Primary
containing three or more hetero rings · CPC title
not condensed and containing further heterocyclic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9624192B2 cover?
- The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
- Who is the assignee on this patent?
- Auberson Yves, Bock Mark Gary, Braga Dario, and 10 more
- What technology area does this patent fall under?
- Primary CPC classification C07D401/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).